stars 1 stars 2 stars 3

Micreos is a platform biotech company focused on discovering and developing recombinant antimicrobial enzymes for chronic dermatological disease Micreos is a pre clinical stage pharmaceutical biotech developing enzymes that selectively kill only harmful bacteria while preserving the rest of the microbiome. Our vision is to positively impact patient care while helping global health care systems to address dermatological conditions with high unmet medical need Our unique capability to optimise enzyme therapeutics means that we have already developed an endolysin based investigational enzyme. These antimicrobials are focused on the detrimental impact of Staphylococcus sp. In dermatology. Our team is forging ahead, partnering across medicine, to realise the shared goal of better solutions to combat harmful bacteria in chronic disease.

Website http://www.micreosgroup.com
Employees 24 (11 on RocketReach)
Founded 2005
Industry Biotechnology Research

Micreos Questions

Martin Vlasaty is the CFO of Micreos.

11 people are employed at Micreos.

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users